• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATX

AMPLIA THERAPEUTICS LIMITED - Charts / Financials

0.00% ! 13.0¢
Market Cap $66.69M  !
Healthcare Biotechnology
Add to My Watchlist

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company's pipeline includes narmafotinib (AMP945) and AMP886. narmafotinib is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company's second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 13.00pm 11/05/2026 (20 minute delay) ?
Day
Open 13.3¢   Day High 13.5¢   Day Low 12.8¢
Daily Volume 370475
Bids   Sellers
Number Price Volume   Number Price Volume
0 12.5¢ 485464   0 13.0¢ 302846

Directors & Senior Management

Mr. Andrew John Cooke Company Secretary
Dr. Christopher J. Burns CEO, MD & Director
Mr. Hamish George Chief Financial Officer
Ms. Jane Catherine Bell Independent Non-Executive Director
Dr. Jason Lickliter Chief Medical Officer
Dr. Jordan D. Berlin Member of Clinical Advisory Board
Dr. Jose L. Iglesias Member of Clinical Advisory Board
Prof. Margaret Frame Member of Scientific Advisory Board
Dr. Mark Devlin Member of Scientific Advisory Board
Dr. Mitesh J. Borad Member of Clinical Advisory Board
Prof. Nick Pavlakis Member of Clinical Advisory Board
Prof. Paul Timpson Member of Scientific Advisory Board
Ms. Rhiannon Jones Chief Operating Officer
Dr. Robert Peach Independent Non-Executive Director
Dr. Warwick Tong Independent Non-Executive Chairman

Data source: ADVFN

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
13.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $66.69M
Open High Low Volume
13.3¢ 13.5¢ 12.8¢ 370.4K

Buyers (Bids)

Vol. Price($)
485464 12.5¢
 

Sellers (Offers)

Price($) Vol.
13.0¢ 302846
Last trade - 13.00pm 11/05/2026 (20 minute delay) ?

Top Stories

Introducing Kaoko Metals: A new high-grade copper play on the ASX

The latest HotCopper Capital Compass, where we've spoken to Kaoko Metals CEO and MD Gerard O'Donovan about the explorer's ASX arrival.
Gold standard: Bison Resources the biggest CY26 ASX IPO story to watch For Bison Resources, things are coming naturally ⁠— and it’s becoming harder and harder to ignore the Australian gold explorer.
WATCH: HotCopper @ 2026 RIU Resources Round-Up − All our from-the-floor interviews HotCopper was at the RIU Resources Round-Up in Sydney, talking to all the ASX-listed companies over the three days in Darling Harbour.
Diablo Resources acquires historic high-grade Horn Silver Project in Utah HotCopper's latest Watchlist, with Diablo CEO Lyle Thorne, talking about the company's new acquisition – the historic, high-grade Horn Silver.
Elevra Lithium agrees to sell Ewoyaa Lithium Project to China's Zhejiang Huayou Cobalt Co Elevra Lithium is divesting from the Ewoyaa Lithium Project in Ghana, selling its interest to China's Zhejiang Huayou Cobalt Co. today.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.